Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.71 USD | -1.33% | -12.19% | -13.52% |
Jun. 03 | Vgxi Inc. Announces Strategic Partnership with Sutro Biopharma Inc. to Support Growing Clinical Pipeline | CI |
May. 13 | Sutro Biopharma Q1 Loss Widens, Revenue Rises | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 254 | 987.9 | 688.5 | 464.4 | 261.5 | 303.5 | - | - |
Enterprise Value (EV) 1 | 146 | 987.9 | 552 | 179.6 | 261.5 | 75.84 | -72.49 | 200.5 |
P/E ratio | -4.53 x | -21.9 x | -6.5 x | -3.44 x | -2.41 x | -1.08 x | -1.16 x | -1.24 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 5.94 x | 23.1 x | 11.1 x | 6.85 x | 1.7 x | 5.11 x | 4.85 x | 3.72 x |
EV / Revenue | 3.42 x | 23.1 x | 8.92 x | 2.65 x | 1.7 x | 1.28 x | -1.16 x | 2.46 x |
EV / EBITDA | -2.88 x | - | -5.89 x | -1.46 x | - | -0.32 x | 0.27 x | - |
EV / FCF | -2.13 x | -13.2 x | -5.69 x | -41.7 x | - | -0.37 x | 0.29 x | -0.88 x |
FCF Yield | -46.9% | -7.58% | -17.6% | -2.4% | - | -270% | 347% | -114% |
Price to Book | 2.6 x | - | - | - | - | 85.2 x | 4.93 x | -3.1 x |
Nbr of stocks (in thousands) | 23,090 | 45,504 | 46,270 | 57,475 | 60,953 | 81,794 | - | - |
Reference price 2 | 11.00 | 21.71 | 14.88 | 8.080 | 4.290 | 3.710 | 3.710 | 3.710 |
Announcement Date | 3/16/20 | 3/18/21 | 2/28/22 | 3/30/23 | 3/25/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 42.74 | 42.72 | 61.88 | 67.77 | 153.7 | 59.38 | 62.54 | 81.65 |
EBITDA 1 | -50.69 | - | -93.68 | -123.3 | - | -234.5 | -264 | - |
EBIT 1 | -55.47 | -71.06 | -98.52 | -128.9 | -89.28 | -228.8 | -262.9 | -261.5 |
Operating Margin | -129.79% | -166.32% | -159.22% | -190.26% | -58.07% | -385.31% | -420.34% | -320.29% |
Earnings before Tax (EBT) 1 | -55.74 | -32.13 | -105.5 | -116.7 | -88.6 | -236.4 | -266.3 | -269.1 |
Net income 1 | -55.74 | -32.13 | -105.5 | -119.2 | -106.8 | -237.8 | -267.6 | -269.4 |
Net margin | -130.44% | -75.2% | -170.55% | -175.89% | -69.47% | -400.56% | -427.89% | -329.9% |
EPS 2 | -2.430 | -0.9900 | -2.290 | -2.350 | -1.780 | -3.429 | -3.198 | -2.994 |
Free Cash Flow 1 | -68.5 | -74.93 | -97 | -4.309 | - | -204.7 | -251.9 | -227.7 |
FCF margin | -160.3% | -175.39% | -156.76% | -6.36% | - | -344.68% | -402.81% | -278.85% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Announcement Date | 3/16/20 | 3/18/21 | 2/28/22 | 3/30/23 | 3/25/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 10.65 | 5.897 | 28.1 | 25.15 | 8.632 | 12.67 | 10.41 | 16.92 | 113.7 | 13.01 | 21.12 | 10.17 | 11.24 | 7.714 | 7.788 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -35.04 | -39.13 | -19.38 | -21.21 | -49.22 | -42.24 | -46.18 | -44.01 | 43.15 | -56.59 | -50.16 | -62.44 | -64.59 | -69.38 | -70.44 |
Operating Margin | -328.85% | -663.59% | -68.97% | -84.34% | -570.23% | -333.26% | -443.52% | -260.07% | 37.95% | -435.05% | -237.51% | -613.72% | -574.49% | -899.46% | -904.47% |
Earnings before Tax (EBT) 1 | -38.12 | -39.11 | -23.51 | -19.49 | -34.59 | -49.66 | -38.37 | -47.44 | 46.87 | -58.21 | -50.31 | -63.78 | -65.67 | -69.82 | -71.07 |
Net income 1 | -38.12 | -39.11 | -26.01 | -19.49 | -34.59 | -50.05 | -38.52 | -49.28 | 31.06 | -58.21 | -51.1 | -63.39 | -66.59 | -69.82 | -71.07 |
Net margin | -357.85% | -663.22% | -92.58% | -77.5% | -400.76% | -394.9% | -370% | -291.21% | 27.32% | -447.52% | -241.96% | -623.12% | -592.28% | -905.08% | -912.6% |
EPS 2 | -0.8300 | -0.8400 | -0.5500 | -0.3700 | -0.6100 | -0.8500 | -0.6400 | -0.8100 | 0.5200 | -0.9500 | -0.7766 | -0.8982 | -0.9144 | -0.9150 | -0.8800 |
Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/28/22 | 5/9/22 | 8/8/22 | 11/8/22 | 3/30/23 | 5/15/23 | 8/10/23 | 11/13/23 | 3/25/24 | 5/13/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 108 | - | 137 | 285 | - | 228 | 376 | 103 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | -68.5 | -74.9 | -97 | -4.31 | - | -205 | -252 | -228 |
ROE (net income / shareholders' equity) | -48.6% | - | - | - | - | -129% | - | - |
ROA (Net income/ Total Assets) | -29.4% | - | - | - | - | -72.6% | -82.4% | -104% |
Assets 1 | 189.8 | - | - | - | - | 327.4 | 324.8 | 258.2 |
Book Value Per Share 2 | 4.230 | - | - | - | - | 0.0400 | 0.7500 | -1.200 |
Cash Flow per Share 2 | -2.830 | - | - | - | - | -3.150 | -2.170 | -1.720 |
Capex 1 | 3.48 | 7.13 | 15.3 | 7.86 | - | 5.79 | 7.44 | 7.19 |
Capex / Sales | 8.15% | 16.69% | 24.76% | 11.59% | - | 9.75% | 11.9% | 8.81% |
Announcement Date | 3/16/20 | 3/18/21 | 2/28/22 | 3/30/23 | 3/25/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.52% | 303M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+2.50% | 22.78B | |
-10.95% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- STRO Stock
- Financials Sutro Biopharma, Inc.